SOAT1 and ulcerative colitis: JAK2, a member of the intracellular tyrosine kinase family, is a potential target in the treatment of ulcerative colitis (Danese et al., 2019), as it regulates pathophysiological processes, such as inflammatory response, apoptosis, and cell cycle, primarily through its involvement in the JAK-STAT signaling pathway.